Rapid Uptake of Targeted Agents Will Drive the Gastric Cancer Drug Market to More Than Double to $1.5 Billion by 2019
WALTHAM, Mass., June 21 /PRNewswire/ — Decision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that the rapid uptake and market penetration of key targeted agents, beginning with Roche/Genentech/Chugai’s Herceptin, will drive the gastric cancer drug market to more than double, from $700 million in 2009 to nearly $1.5 billion in 2019.
The Pharmacor 2010 findings from the topic entitled Gastric Cancer reveal that the robust uptake of Herceptin, which gained European approval for the indication earlier this year, marks the beginning of a new era of targeted treatment for gastric cancer. By 2014, the launch of Bristol-Myers Squibb/Eli Lilly/ImClone Systems/Merck KGaA’s Erbitux, GlaxoSmithKline’s Tykerb/Tyverb and Novartis’s Afinitor and Eli Lilly/ImClone Systems’ IMC-1121B (ramucirumab) will also drive significant market growth. In 2019, combined sales of these premium-priced targeted agents will account for more than half of the gastric cancer drug market in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.
The Pharmacor 2010 findings also reveal that, although the clinical trial failure of Roche/Genentech/Chugai’s Avastin will significantly dent the company’s overall sales potential in this space, these companies are poised to become major players in this market, following the launch of Herceptin.
“In 2009, Roche/Genentech/Chugai held 13 percent of the gastric cancer market owing to sales of Xeloda,” said Decision Resources Analyst Rachel Webster, D.Phil. “In 2014, Roche/Genentech/Chugai will capture nearly one-third of the overall market, owing to increasing sales of Xeloda and the rapid emergence of Herceptin.”
Pharmacor Analyst Call
Media members are welcome to attend our upcoming Pharmacor analyst call entitled What Impact Will the Emergence of Herceptin and Other Targeted Therapies Have on the Gastric Cancer Drug Market? This online presentation will be held on June 28, 2010 at 10 a.m. U.S. Eastern Time. For more information, please contact Christopher Comfort at firstname.lastname@example.org.
About Pharmacor 2010
The newly redesigned Pharmacor advisory service offers clients in the biopharmaceutical industry the most up-to-date information available on commercially significant disease topics.
About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.
About Decision Resources, Inc.
Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact: Decision Resources, Inc. Christopher Comfort 781-296-2597 email@example.com
SOURCE Decision Resources